US Broker Ratings

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Navigating Growth in the Generics Market

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX), a prominent player in the healthcare sector, operates within the niche of drug manufacturers specializing in both specialty and generic pharmaceuticals. With a market capitalization..

Alvotech (ALVO) Investor Outlook: Exploring a 331% Potential Upside in the Biosimilars Market

Alvotech (NASDAQ: ALVO) stands out in the healthcare sector as a burgeoning force in the biosimilars market, poised for significant growth. With a market capitalization of $1.6 billion, Alvotech operates..

Merus N.V. (MRUS) Stock Analysis: Evaluating a 7.78% Potential Upside in the Biotech Sector

Merus N.V. (MRUS), a biotechnology company at the forefront of immuno-oncology, presents an intriguing opportunity for investors keen on the healthcare sector. Headquartered in Utrecht, Netherlands, Merus is dedicated to..

NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 40% Upside Potential in Biotech Innovation

NewAmsterdam Pharma Company N.V. (NAMS) is making waves in the biotechnology sector with its innovative approach to treating metabolic diseases. As a late-stage biopharmaceutical company headquartered in Naarden, Netherlands, NewAmsterdam..

Concentra Group Holdings (CON): Analyzing a 23% Upside Potential in Healthcare

Concentra Group Holdings Parent, Inc. (CON) is positioning itself as a formidable player in the healthcare sector, specifically within the medical care facilities industry. Based in Addison, Texas, this company..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: Exploring a 67.85% Potential Upside in the Biotechnology Sector

Apogee Therapeutics, Inc. (NASDAQ: APGE), a burgeoning player in the biotechnology industry, has captured the attention of investors with its promising pipeline of innovative therapies and a market capitalization of..

ImmunityBio, Inc. (IBRX) Investor Outlook: Analyzing the 70% Upside Potential in Biotech Innovation

ImmunityBio, Inc. (NASDAQ: IBRX) is capturing the attention of investors with its innovative approach in the biotechnology sector, especially as it navigates through the healthcare landscape with its cutting-edge immunotherapy..

Arcellx, Inc. (ACLX) Investor Outlook: Analysts See 63% Upside Potential for Biotech Innovator

Arcellx, Inc. (NASDAQ: ACLX), a dynamic player in the biotechnology sector, is capturing the attention of investors with a compelling upside potential of 63.3%. Specializing in the development of innovative..

Scholar Rock Holding Corporation (SRRK) Stock Analysis: A Biotechnology Contender with a 5.24% Upside

Scholar Rock Holding Corporation (NASDAQ: SRRK) is turning heads in the biotechnology sector with its innovative approach to drug development. Headquartered in Cambridge, Massachusetts, this biopharmaceutical company is focused on..

ICU Medical, Inc. (ICUI) Stock Analysis: Exploring a 19% Upside Potential in the Healthcare Sector

ICU Medical, Inc. (NASDAQ: ICUI), a prominent player in the healthcare sector specializing in medical instruments and supplies, represents a compelling opportunity for investors seeking growth in a turbulent market...

Envista Holdings Corporation (NVST) Stock Analysis: Is Its Current Valuation Justified?

Envista Holdings Corporation (NYSE: NVST) stands as a formidable player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $4.88 billion, Envista..

Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Strong Buy Ratings and 31.57% Potential Upside

Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a cutting-edge player in the biotechnology sector, is making waves with its neuroscience-focused approach to therapeutics. Headquartered in Burnaby, Canada, Xenon Pharmaceuticals is dedicated to..

Zai Lab Limited (ZLAB) Stock Analysis: Exploring a 137.94% Potential Upside in the Biotech Sector

Zai Lab Limited (NASDAQ: ZLAB), a notable player in the biotechnology industry, is capturing the attention of investors with its promising potential upside of 137.94%. As a biopharmaceutical leader headquartered..

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis: Unpacking a 73.66% Potential Upside

For investors with an interest in innovative healthcare solutions, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) offers a compelling narrative. Specializing in surgical robotics, PROCEPT is making significant inroads in the medical..

Haemonetics Corporation (HAE) Stock Analysis: Exploring a 52.54% Potential Upside in the Medical Devices Sector

Haemonetics Corporation (NYSE: HAE), a prominent player in the healthcare sector, specifically within the medical devices industry, stands out with a market capitalization of $2.7 billion. Known for its cutting-edge..

Metsera, Inc. (MTSR) Stock Analysis: Navigating the -19.15% Potential Downside in the Biotechnology Sector

Metsera, Inc. (MTSR) stands out in the biotechnology sector with its innovative approach to addressing obesity and related diseases through the development of hormone analog peptides. As a clinical-stage company,..

Viking Therapeutics, Inc. (VKTX) Stock Analysis: Uncovering a 218% Upside Potential in Biotech

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, is gaining significant attention in the investor community due to its promising pipeline and remarkable upside potential. With a market cap..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Unpacking a 36.64% Potential Upside in Rare Disease Biotech

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is gaining attention from investors with its significant potential upside of 36.64%, according to the latest analyst ratings. This Boston-based biotechnology company is focused on..

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Is a 15.86% Potential Upside Enough to Attract Investors?

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has made a name for itself in the biotechnology sector, focusing on groundbreaking RNA-targeted therapeutics and gene therapies for rare diseases. As a commercial-stage biopharmaceutical..

Krystal Biotech, Inc. (KRYS) Investor Outlook: A Promising Biotech with a 6% Upside Potential

Krystal Biotech, Inc. (NASDAQ: KRYS) is making waves in the biotechnology sector with its focus on developing genetic medicines for diseases with significant unmet medical needs. With a market capitalization..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds